Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

AVXL Anavex Life Sciences

10.320
+0.570+5.85%
Close 09/30 16:00 ET
10.380
+0.060+0.58%
Post Mkt Price 09/30 16:39 ET
High
10.660
Open
9.550
Turnover
10.80M
Low
9.550
Pre Close
9.750
Volume
1.05M
Market Cap
804.37M
P/E(TTM)
Loss
52wk High
23.730
Shares
77.94M
P/E(Static)
Loss
52wk Low
7.130
Float Cap
780.12M
Bid/Ask %
67.57%
Historical High
31.500
Shs Float
75.59M
Volume Ratio
1.03
Historical Low
0.600
Dividend TTM
--
Div Yield TTM
--
P/B
5.34
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.39%
Amplitude
11.39%
Avg Price
10.312
Lot Size
1
Float Cap
780.12M
Bid/Ask %
67.57%
Historical High
31.500
Shs Float
75.59M
Volume Ratio
1.03
Historical Low
0.600
Dividend TTM
--
P/B
5.34
Dividend LFY
--
Turnover Ratio
1.39%
Amplitude
11.39%
Avg Price
10.312
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
CEO: Mr. Christopher U. Missling,PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...